Dow Up0.76% Nasdaq Up0.69%

Progenics Pharmaceuticals, Inc. (PGNX)

-NasdaqGS
4.72 Up 0.11(2.39%) Oct 24, 3:59PM EDT
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period EndingJun 30, 2014Mar 31, 2014Dec 31, 2013Sep 30, 2013
Total Revenue 1,477   1,815   2,968   867  
Cost of Revenue180  90  253  91  
Gross Profit 1,297   1,725   2,715   776  
Operating Expenses
Research Development7,833  6,934  7,201  8,402  
Selling General and Administrative4,271  3,890  3,956  2,634  
Non Recurring147  82  316  73  
Others133  144  165  179  
Total Operating Expenses12,384  11,050  11,638  11,288  
Operating Income or Loss (11,087) (9,325) (8,923) (10,512)
Income from Continuing Operations
Total Other Income/Expenses Net13  12  10  12  
Earnings Before Interest And Taxes(11,074)(9,313)(8,913)(10,500)
Interest Expense -   -   -   -  
Income Before Tax(11,074)(9,313)(8,913)(10,500)
Income Tax Expense(1) -  (362) -  
Minority Interest -   -   -   -  
Net Income From Continuing Ops(11,073)(9,313)(8,551)(10,500)
Non-recurring Events
Discontinued Operations -   -   -   -  
Extraordinary Items -   -   -   -  
Effect Of Accounting Changes -   -   -   -  
Other Items -   -   -   -  
Net Income (11,073) (9,313) (8,551) (10,500)
Preferred Stock And Other Adjustments -   -   -   -  
Net Income Applicable To Common Shares (11,073) (9,313) (8,551) (10,500)

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.